Understanding Factor V Leiden and Prothrombin Mutations
Part of Blood & lymphatic clinical trials.
This study helps researchers learn more about two inherited blood-clotting conditions: Factor V Leiden and Prothrombin G20210A mutations. By participating, you'll help doctors better understand these conditions and how they affect people's health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with or suspect you have Factor V Leiden or Prothrombin G20210A mutation (confirmed by genetic testing)
- You are willing and able to complete study visits and assessments as scheduled
- You can provide written informed consent before starting the study
- You do not have other serious medical conditions that might make participation unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called CITY-FXI to see if it is safe and well tolerated in people who are at higher risk of blood clots, including those with certain genetic mutations or a past blood clot. It helps doctors find the right dose for future studies.
This study looks at genes and blood function in people with inherited (passed-down) problems with platelets, white blood cells, or blood clotting. It may help improve understanding of the cause of these conditions and how they work in the body.
This study collects health information and blood samples from people with factor X deficiency (a rare bleeding disorder) and their close family members. The goal is to learn more about how the condition progresses over time, which could lead to better treatment and management.
This trial aims to learn more about blood clots, inflammation, and blood vessel problems. It may help researchers better understand these conditions and how they affect people.
This study looks at a specific gene mutation in people with polycythemia vera (PV) or essential thrombocythemia (ET) to understand how it may relate to blood clots. It mainly involves collecting blood samples and joining a medical registry, before clot-lowering medicines start.
This trial uses stored blood samples to see how well different lab tests measure clotting when someone has a factor deficiency (like low levels of clotting proteins) or liver damage. It may help doctors choose the most accurate test for these situations.
Hear when a new Factor V Leiden trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.